Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences reported a strengthened cash position of $377.7 million, extending its runway into mid-2028, supported by $60.8 million in ATM proceeds during the first half of 2026. The company initiated dosing in the Phase 3 IMPACT DUCHENNE trial for SGT-003 and plans to meet with the FDA in late Q4 2026 to discuss an accelerated approval pathway.
Key figures
- Net loss
- 54799000
- Cash runway
- mid-2028
- Ga expenses
- 13119000
- Rd expenses
- 44265000
- Atm proceeds
- 60800000
- Cash position
- 377700000
- Shares outstanding
- 105125366
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.